A study of impact of low dose albumin infusion on outcome in patients with cirrhosis and sepsis

A study of impact of fixed dose albumin infusion on outcome in patients with cirrhosis and sepsis.

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/03/023794

Enrollment

174

Registered

2020-03-05

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K746- Other and unspecified cirrhosis ofliver

Interventions

Intervention1: Albumin: Albumin 20 % infusion 20gms/day for 5 days Control Intervention1: Albumin: Albumin infusion 20 % 1.5gm/kg/ body weight on day one and ,1gm/kg/body weight on day three.

Eligibility

Inclusion criteria

Inclusion criteria: Patients giving informed consent >18 years All etiologies of cirrhosis with Sepsis

Exclusion criteria

Exclusion criteria: Patients with mean arterial pressure Congestive heart failure with ejection fraction Hepatocellular carcinoma Chronic kidney disease with Serum creatinine >2mg/dl Mechanical ventilation at inclusion time Refusal to participate

Design outcomes

Primary

Measure	Time frame
In hospital mortality.Timepoint: Time of discharge/ Death	—

Secondary

Measure	Time frame
Mortality at day 30, Improvement in sepsis and morbidity. Examples-hypotension, pneumonia, serum creatine, INR, sensorium, serum bilirubin. Timepoint: Mortality at day 30	—

Countries

India

Contacts

Public ContactDr Bipadabhanjan Mallick

Kalinga institute of medical sciences

drbipadabhanjan@gmail.com9592153718

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 10, 2026